0
MicroSintesis and Bio Agri Mix have signed a distribution agreement to market a unique Proteobiotic technology for Canadian swine production.
Nuvio is the first product made of protein sources that contain probiotic molecules, termed Proteobiotics, which have been proven in clinical trials to significantly improve producer outcomes when faced with post-weaning diarrhea challenges.
Bacteria use a mechanism called Quorum Sensing that lets them communicate with each other and act as a unified group. This communication process enables bacteria to express virulence factors such as biofilm formation, adhesion, invasion and toxin release. Proteobiotics use a non-antibiotic, anti-infective mode of action that supports the gut's natural immune defences by stopping the cell-to-cell communication of these bacteria. In recent trials, the product was 86% effective at reducing clinical diarrhea symptoms with statistically significant improvements in weight gain and feed conversion during the trial period.
Initially discovered at the University of Guelph, the development of the product has been a collaborative effort between MicroSintesis and the University of Guelph, and has been independently validated in clinical research studies as well as in a veterinary monitored commercial field trial.
"Nuvio has the potential to be a new, first-line product in the fight against the production problems associated with post-weaning diarrhea," said Trevor Lank, Swine Technical Consultant for MicroSintesis. "It can be easily administered with other products such as vaccines or antibiotics without withdrawal periods, and because the proteobiotics work on reducing bacteria communication, no period for immunity building is required. The proteobiotics simultaneously reduce the pathogenic bacteria's effectiveness while increasing the ratio of the natural gut flora. It is truly an all-in-one technology."
Dr. Robert Bell, CEO of Bio Agri Mix, added, "Over my forty-year career in the animal health industry, I have witnessed the launch of a handful of revolutionary technologies; endectocides, prostaglandins and long-lasting time dependent antimicrobials, and there is no doubt Nuvio is in the same league with these game-changing products, particularly when the animal health industry is tasked with ensuring prudent antimicrobial use and reduced antimicrobial resistance. Nuvio has been proven to be clinically effective in conventional swine systems and will fill a unique void for "raised without antimicrobial" swine production."
"MicroSintesis is delighted to have partnered with Bio Agri Mix on the commercialization of this technology. Bio Agri Mix has a proven track record not only in marketing water solubles, but has a strong commitment to leading the way through the changing antimicrobial-use regulations," said Hannah McIver, CEO of MicroSintesis.
Nuvio is administered in the drinking water for the first 14 days post-weaning. It will be available through veterinarians and feed companies beginning October 2017.
October 5, 2017 - MicroSintesis.
